Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged < 24 months hospitalised for severe acute respiratory infection in three European countries. The overall effectiveness in the 2024/25 season among 2,201 children was 79% (95% CI: 58 to 89) and 85%, 78% and 69% at < 30, 30-89 and 90-215 days since immunisation. Immunisation was effective for preventing RSV-related hospitalisation in children, but effectiveness by time since immunisation needs monitoring in future seasons.
Authors
- Marie-Laure Parsy
- Adrien Lajot (ORCID: https://orcid.org/0000-0001-9614-2641)
- Mathil Vandromme (ORCID: https://orcid.org/0000-0001-6033-246X)
- Sabrina Bacci (ORCID: https://orcid.org/0000-0002-6575-3439)
- Nathalie Nicolay (ORCID: https://orcid.org/0000-0002-5916-7855)
- Vânia Gaio (ORCID: https://orcid.org/0000-0001-7626-4991)
- Jesús Castilla
- Aitziber Echeverría (ORCID: https://orcid.org/0009-0002-2822-819X)
- Sandra O. Campos
- Marta Cara-Rodríguez
- Ana Roldan Garrido
- Raquel Guiomar
- Camelia Savulescu
- Ana Paula Rodrigues
- Iris Ganser
- Iván Martínez-Baz
- Angela Mc Rose
- VEBIS hospital network RSV IE group
Publication Details
- Journal
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
- Published
- 2025-11-13
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00